Keywords
rifaximin
small intestinal bacterial overgrowth syndrome
Abstract
Small intestinal bacterial overgrowth syndrome (SIBO) is a clinical syndrome characterized by increased number and/ or abnormal type of bacteria in the small bowel. Various etiological processes can disturb the mechanisms which keep the number of bacteria in the upper part of gastrointestinal tract low and thereby can lead to SIBO. Clinically, SIBO manifests with symptoms that arise due to a bacterial overload on normal functions of the upper gastrointestinal tract. Prompt recognition and adequate early treatment (correction of the underlying disease, antibiotic therapy and nutritional support) should be aimed at prevention and reversal of malabsorption process.References
1. Bures J, Cyrany J, Kohoutova D et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16(24): 2978– 2990.
2. Gregg CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002; 13(4): 200– 209.
3. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361(9356): 512– 519.
4. Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol 2004; 268: 491– 502.
5. Meyers JS, Ehrenpreis ED, Craig RM. Small intestinal bacterial overgrowth syndrome. Curr Treat Options Gastroenterol 2001; 4(1): 7– 14.
6. Quigley EM, Abu‑ Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24(4): 943– 959. doi: 10.1016/ j.idc. 2010.07.007.
7. Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome‑related symptoms: experience with Rifaximin. World J Gastroenterol 2009; 15(21): 2628– 2631.
8. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009; 18(3): 349– 358. doi: 10.1517/ 13543780902780175.
9. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130 (2 Suppl 1): S78– S90.